2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-121441
    Fispemifene 341524-89-8 99.67%
    Fispemifene, an orally active selective estrogen receptor modulator with anti-inflammatory and antiestrogenic action, attenuates glandular inflammation in an animal model of chronic nonbacterial prostatitis.
    Fispemifene
  • HY-121837
    β2AR-IN-15 2088234-50-6 98.84%
    β2AR-IN-15 is a selective β2-adrenergic receptor (β2AR) antagonist with a Kd of 1.7 μM. β2AR-IN-15 binds to an intracellular β2AR region overlapping the G-protein binding site, enhancing orthosteric inverse agonist binding while negatively modulating binding of orthosteric agonists with EC50 values of 1.9 and 0.48 μM. β2AR-IN-15 shows inhibitory effect on cAMP production and β-arrestin recruitment to activated β2AR. β2AR-IN-15 can be used for the research of cardiovascular and pulmonary diseases.
    β2AR-IN-15
  • HY-123115
    Leucrose 7158-70-5 98.53%
    Leucrose (5-O-α-D-Glucopyranosyl-D-fructose) is an orally active Sucrose (HY-B1779) isomer naturally found in pollen and honey. Leucrose promotes phosphorylation of JAK1 and STAT6, reduces pro-inflammatory mediators and cytokinesas (TNFα, and IL-1β), increases M2 macrophage polarization and suppresses DSS (HY-116282C)-induced colitis. Leucrose suppresses hepatic triglyceride accumulation, improves fasting blood glucose levels, and regulates hepatic lipogenesis and fatty acid β-oxidation in high-fat diet-induced obese mice. Leucrose is slowly hydrolyzed into glucose and fructose by α-glucosidase and acts as as a sugar substitute in diet.
    Leucrose
  • HY-12335A
    UNC0379 TFA 1620401-83-3 99.91%
    UNC0379 TFA is a selective, substrate-competitive inhibitor of lysine methyltransferase SETD8 (KMT5A) with an IC50 of 7.3 μM, KD value of 18.3 μM. UNC0379 TFA can be used in the research of inflammation and cancers, such as pulmonary fibrosis, ovarian cancer, neuroblastoma.
    UNC0379 TFA
  • HY-124146
    BI1002494 1319738-39-0 98%
    BI1002494 is an orally active, potent, and selective spleen tyrosine kinase (SYK) inhibitor. BI 1002494 exhibits an IC50 of 115 nM in inhibiting high-affinity IgE receptor-mediated mast cell and basophil degranulation. BI1002494 can be utilized in immunology reesearch.
    BI1002494
  • HY-12530R
    Velpatasvir (Standard) 1377049-84-7 99.68%
    Velpatasvir (Standard) is the analytical standard of Velpatasvir. This product is intended for research and analytical applications. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.16 μM.
    Velpatasvir (Standard)
  • HY-125538
    Deoxybrevianamide E 34610-68-9 99.2%
    Deoxybrevianamide E, an indole alkaloid, is a biosynthetic precursor for advanced metabolites isolated from the marine-derived Aspergillus sp..
    Deoxybrevianamide E
  • HY-127125
    Diclofenac ethyl ester 15307-77-4 99.28%
    Diclofenac ethyl ester is the prodrug of Diclofenac (HY-15036), that is encapsulated in polymer micelles in vitro, and released with prolonged circulation time and reduced drug concentrations in the heart and kidneys in vivo.
    Diclofenac ethyl ester
  • HY-129629
    Thiomandelic acid 4695-09-4
    Thiomandelic acid is a broad spectrum inhibitor of Zinc -lactamases.
    Thiomandelic acid
  • HY-13010S
    Laquinimod-d5 1214267-09-0 98.25%
    Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research.
    Laquinimod-d5
  • HY-130429
    14,15-Leukotriene C4 75290-60-7 98.9%
    14,15-Leukotriene C4 (Eoxin C4) is a Leukotriene compound produced by the enzymatic reaction of arachidonic acid. 14,15-Leukotriene C4 has the activity of promoting inflammatory response. 14,15-Leukotriene C4 can increase the permeability of blood vessels, causing fluid and white blood cells to leak out of the blood vessels, which increases the number of inflammatory cells in the tissue. 14,15-Leukotriene C4 can be used in studies of asthma and other inflammatory diseases.
    14,15-Leukotriene C4
  • HY-130786
    Denbufylline 57076-71-8 99.92%
    Denbufylline (BRL 30892) is an inhibitor of phosphodiesterase-4 (PDE4). Denbufylline is able to block the degradation of intracellular cAMP (cyclic adenosine phosphate) thereby increasing the level of intracellular cAMP, which helps regulate a variety of cellular functions. Denbufylline can be used in the study of chronic obstructive pulmonary disease (COPD), asthma and other inflammatory diseases.
    Denbufylline
  • HY-13205R
    Belnacasan (Standard) 273404-37-8 99.97%
    Belnacasan (Standard) is the analytical standard of Belnacasan. This product is intended for research and analytical applications. Belnacasan (VX-765) is an orally bioactive proagent of VRT-043198, which is a potent and selective inhibitor of IL-converting enzyme (ICE)/caspase-1 with Kis of 0.8 nM and less than 0.6 nM for caspase-1 and caspase-4, respectively. Belnacasan (VX-765) inhibits the release of LPS-induced IL-1β and IL-18 by human PBMCs with an IC50 of ~0.7 μM.
    Belnacasan (Standard)
  • HY-132130
    BRD4 Inhibitor-13 218934-50-0 99.08%
    BRD4 Inhibitor-13 (Compound 2) is a BRD4 ligand, and can be used for research of cancer, inflammation.
    BRD4 Inhibitor-13
  • HY-132132
    Neutrophil elastase inhibitor 3 1234707-32-4
    Neutrophil elastase inhibitor 3 (compound 13), a benzoxazinone analog, shows effects on superoxide anion generation and exhibits as a neutrophil elastase (NE) inhibitor, with an IC50 of 80.8 nM for NE release.
    Neutrophil elastase inhibitor 3
  • HY-13278A
    IRAK inhibitor 4 (trans) 2070014-89-8 99.02%
    IRAK inhibitor 4 (trans) is the trans form of IRAK inhibitor 4. IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor.
    IRAK inhibitor 4 (trans)
  • HY-133594
    Sandaracopimaric acid 471-74-9 98.86%
    Sandaracopimaric acid is a diterpenoid with anti-inflammatory effect. Sandaracopimaric acid reduces the contraction of phenylephrine-induced pulmonary arteries with an EC50 of 43.93 μM.
    Sandaracopimaric acid
  • HY-133724
    Vardenafil N-oxide 448184-48-3 99.57%
    Vardenafil N-oxide is a N-Oxide impurity of Vardenafil (HY-B0442).
    Vardenafil N-oxide
  • HY-13662A
    Lansoprazole sodium 226904-00-3 98.80%
    Lansoprazole sodium (AG 1749 sodium) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole sodium (AG 1749 sodium) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).
    Lansoprazole sodium
  • HY-137197
    6β-Hydroxy dexamethasone 55879-47-5 99.03%
    6β-Hydroxy dexamethasone is an active metabolite of the synthetic glucocorticoid Dexamethasone (HY-14648).
    6β-Hydroxy dexamethasone
Cat. No. Product Name / Synonyms Application Reactivity